查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1611100

器官移植用免疫抑制劑的市場規模、佔有率和趨勢分析報告：按藥物類別、移植類型、地區和細分市場預測，2025-2030年

Organ Transplant Immunosuppressant Drugs Market Size, Share & Trends Analysis Report By Drug Class (Calcineurin Inhibitors, Antiproliferative Agents), By Transplant Type, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 110 Pages | 商品交期: 2-10個工作天內

價格

器官移植免疫抑制劑市場的成長與趨勢

Grand View Research, Inc.最新報告顯示，預計2030年全球器官移植免疫抑制劑市場規模將達72.4億美元，2025年至2030年複合年成長率為4.7%。市場成長是由需要器官移植的患者數量的增加和新產品核准的增加所推動的。然而，移植手術成本高昂、器官供需失衡以及報銷情況不確定是限制市場成長的主要因素。

根據衛生資源與服務管理局以及美國衛生與公眾服務部的數據，截至 2019 年 1 月，超過 113,000 人需要移植，2018 年進行了 36,528 例移植手術。因此，器官移植的需求龐大，有望進一步推動市場。腎臟移植在移植領域佔據最大的市場佔有率，預計在整個預測期內將保持領先。這是由於腎臟的需求增加和比其他器官相對更好的可得性。

按藥物類別分類，Calcineurin抑制劑預計將在預測期內主導全球器官移植免疫抑制劑市場。此藥物類別中有兩種藥物： Prograf（Tacrolimus）和 Sandimmune（Cyclosporine）。儘管這些有效的免疫抑制劑已在腎臟移植患者中使用了 20 多年，但它們的毒性特徵差異很大。預計亞太地區的複合年成長率最高，而北美地區預計在預測期內佔據最大佔有率。

器官移植免疫抑制劑市場報告亮點

  • 按藥物類別分類，Calcineurin抑制劑預計將佔據最大的市場佔有率。Calcineurin抑制劑透過Calcineurin酶阻斷免疫系統 T 細胞的活化。
  • Calcineurin抑制劑，如Tacrolimus和Cyclosporine，是腎臟移植中免疫抑制的基石。在超過 85% 的腎臟移植病例中，Tacrolimus被納入患者維持免疫抑制方案的一部分。
  • 依移植類型分類，腎臟移植佔最大市場佔有率，2024年將達49.1%。
  • 由於人均醫療保健支出的增加、醫療保健基礎設施的改善以及該地區器官移植需求的增加，預計亞太市場將在預測期內呈現最快的成長。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章器官移植免疫抑制劑市場的變數、趨勢和範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 營商環境分析
    • 產業分析-波特五力分析
    • PESTLE分析

第4章器官移植免疫抑制劑市場：藥物類別的商業分析

  • 2024年及2030年藥品類別市場佔有率
  • 藥品類別細分儀表板
  • 2018-2030 年按藥物類別分類的市場規模、預測與趨勢分析
  • Calcineurin抑制劑
  • 抗增殖劑
  • mTOR抑制劑
  • 類固醇
  • 其他

第5章器官移植免疫抑制劑市場：移植類型業務分析

  • 2024 年和 2030 年攜帶式類型市場佔有率
  • 攜帶式細分儀表板
  • 2018-2030 年市場規模、預測與趨勢分析（按移植類型）
  • 腎
  • 肝
  • 心
  • 肺
  • 胰臟
  • 其他連接埠類型

第6章器官移植免疫抑制劑市場：按藥物類別分類的區域估計和趨勢分析

  • 2024 年及 2030 年按地區分類的市場佔有率分析
  • 區域市場儀表板
  • 2018-2030年市場規模及預測趨勢分析
  • 北美洲
    • 按國家/地區分類，2018-2030
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 按國家/地區分類，2018-2030
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 丹麥
    • 瑞典
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 按國家/地區分類，2018-2030
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 按國家/地區分類，2018-2030
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭格局

  • 參與者概覽
  • 公司市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介/上市公司
    • Astellas Pharma doo
    • Sanofi
    • Accord Healthcare
    • Novartis AG
    • Viatris Inc.
    • F. Hoffmann-La Roche Ltd
    • GlaxoSmithKline plc.
    • Veloxis Pharmaceuticals, Inc.
    • Bristol-Myers Squibb Company
Product Code: GVR-3-68038-786-5

Organ Transplant Immunosuppressant Drugs Market Growth & Trends:

The global organ transplant immunosuppressant drugs market size is estimated to reach USD 7.24 billion by 2030, registering a CAGR of 4.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. Growing patient population requiring organ transplantations and increasing approval of novel products are the factors driving the market growth. However, the high procedural cost of transplantations, the disproportion in the supply and demand for organs, and uncertain reimbursement scenario are the major factors restraining the market growth.

According to the Health Resources & Services Administration and the U.S. Department of Health and Human Services, more than 113,000 people were in need of transplants as of January 2019 and 36,528 transplants were performed in 2018. Hence, there is huge demand for organ transplants that will further boost the market. Kidney transplant held the largest market share in the transplant segment and is expected to retain its leading position through the forecast period. This can be attributed to increasing demand and comparatively better availability of kidneys than other organs.

Among the drug classes, the calcineurin inhibitors are expected to dominate the global organ transplant immunosuppressant drugs market through the forecast period. There are two drugs in this drug class, Prograf (tacrolimus) and Neoral/Sandimmune (cyclosporine). Although these effective immunosuppressants have been used in kidney transplant recipients for more than 20 years, they hold extensive toxicity profiles. Asia Pacific is expected to show the highest CAGR, while North America is expected to hold the largest share during the forecast period.

Organ Transplant Immunosuppressant Drugs Market Report Highlights:

  • Calcineurin inhibitors are expected to command the largest market share in the drug class segment. Calcineurin inhibitors inhibit the activation action of T-cells of the immune system by the enzyme calcineurin.
  • Calcineurin inhibitors such as tacrolimus and cyclosporine are the cornerstone of immunosuppression for kidney transplantation. In more than 85% cases of kidney transplant, tacrolimus is prescribed as a part of the patients' maintenance immunosuppressive regimen.
  • Based on transplant type, the kidney transplant held the largest market share of 49.1% in 2024, due to the increasing demand for kidney replacement procedures
  • Asia Pacific regional market is expected to demonstrate the fastest growth over the forecast period due to rising per capita healthcare expenditure, improving healthcare infrastructure, and increasing demand for organ transplantations in the region.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Transplant Type
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Organ Transplant Immunosuppressant Drugs Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Organ Transplant Immunosuppressant Drugs Market: Drug Class Business Analysis

  • 4.1. Drug Class Market Share, 2024 & 2030
  • 4.2. Drug Class Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
  • 4.4. Calcineurin Inhibitors
    • 4.4.1. Calcineurin Inhibitors Market, 2018 - 2030 (USD Million)
  • 4.5. Antiproliferative Agents
    • 4.5.1. Antiproliferative Agents Market, 2018 - 2030 (USD Million)
  • 4.6. mTOR Inhibitor
    • 4.6.1. mTOR Inhibitor Market, 2018 - 2030 (USD Million)
  • 4.7. Steroids
    • 4.7.1. Steroids Market, 2018 - 2030 (USD Million)
  • 4.8. Other Drug Classes
    • 4.8.1. Other Drug Classes Market, 2018 - 2030 (USD Million)

Chapter 5. Organ Transplant Immunosuppressant Drugs Market: Transplant Type Business Analysis

  • 5.1. Transplant Type Market Share, 2024 & 2030
  • 5.2. Transplant Type Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Transplant Type, 2018 to 2030 (USD Million)
  • 5.4. Kidney
    • 5.4.1. Kidney Market, 2018 - 2030 (USD Million)
  • 5.5. Liver
    • 5.5.1. Liver Market, 2018 - 2030 (USD Million)
  • 5.6. Heart
    • 5.6.1. Heart Market, 2018 - 2030 (USD Million)
  • 5.7. Lung
    • 5.7.1. Lung Market, 2018 - 2030 (USD Million)
  • 5.8. Pancreas
    • 5.8.1. Pancreas Market, 2018 - 2030 (USD Million)
  • 5.9. Other Transplant Types
    • 5.9.1. Other Transplant Types Market, 2018 - 2030 (USD Million)

Chapter 6. Organ Transplant Immunosuppressant Drugs Market: Regional Estimates & Trend Analysis by Drug Class and Transplant Type

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 6.4. North America
    • 6.4.1. North America Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Regulatory Framework
      • 6.4.2.3. Competitive Insights
      • 6.4.2.4. U.S. Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Regulatory Framework
      • 6.4.3.3. Competitive Insights
      • 6.4.3.4. Canada Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Regulatory Framework
      • 6.4.4.3. Competitive Insights
      • 6.4.4.4. Mexico Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Regulatory Framework
      • 6.5.2.3. Competitive Insights
      • 6.5.2.4. UK Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Regulatory Framework
      • 6.5.3.3. Competitive Insights
      • 6.5.3.4. Germany Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Regulatory Framework
      • 6.5.4.3. Competitive Insights
      • 6.5.4.4. France Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Regulatory Framework
      • 6.5.5.3. Competitive Insights
      • 6.5.5.4. Italy Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Regulatory Framework
      • 6.5.6.3. Competitive Insights
      • 6.5.6.4. Spain Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Norway
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Regulatory Framework
      • 6.5.7.3. Competitive Insights
      • 6.5.7.4. Norway Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Denmark
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Regulatory Framework
      • 6.5.8.3. Competitive Insights
      • 6.5.8.4. Denmark Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.9. Sweden
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Regulatory Framework
      • 6.5.9.3. Competitive Insights
      • 6.5.9.4. Sweden Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Regulatory Framework
      • 6.6.2.3. Competitive Insights
      • 6.6.2.4. Japan Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Regulatory Framework
      • 6.6.3.3. Competitive Insights
      • 6.6.3.4. China Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Regulatory Framework
      • 6.6.4.3. Competitive Insights
      • 6.6.4.4. India Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Regulatory Framework
      • 6.6.5.3. Competitive Insights
      • 6.6.5.4. Australia Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Regulatory Framework
      • 6.6.6.3. Competitive Insights
      • 6.6.6.4. South Korea Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Regulatory Framework
      • 6.6.7.3. Competitive Insights
      • 6.6.7.4. Thailand Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Regulatory Framework
      • 6.7.2.3. Competitive Insights
      • 6.7.2.4. Brazil Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Regulatory Framework
      • 6.7.3.3. Competitive Insights
      • 6.7.3.4. Argentina Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8. MEA
    • 6.8.1. MEA Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Regulatory Framework
      • 6.8.2.3. Competitive Insights
      • 6.8.2.4. South Africa Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Regulatory Framework
      • 6.8.3.3. Competitive Insights
      • 6.8.3.4. Saudi Arabia Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Regulatory Framework
      • 6.8.4.3. Competitive Insights
      • 6.8.4.4. UAE Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Regulatory Framework
      • 6.8.5.3. Competitive Insights
      • 6.8.5.4. Kuwait Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Astellas Pharma d.o.o.
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Sanofi
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Accord Healthcare
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Novartis AG
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Viatris Inc.
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. F. Hoffmann-La Roche Ltd
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. GlaxoSmithKline plc.
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Veloxis Pharmaceuticals, Inc.
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Bristol-Myers Squibb Company
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global organ transplant immunosuppressant drugs market, by region, 2018 - 2030 (USD Million)
  • Table 4. Global organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 5. Global organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
  • Table 6. North America organ transplant immunosuppressant drugs market, by country, 2018 - 2030 (USD Million)
  • Table 7. North America organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 8. North America organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
  • Table 9. U.S. organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 10. U.S. organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
  • Table 11. Canada organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 12. Canada organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
  • Table 13. Mexico organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 14. Mexico organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
  • Table 15. Europe organ transplant immunosuppressant drugs market, by country, 2018 - 2030 (USD Million)
  • Table 16. Europe organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 17. Europe organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
  • Table 18. UK organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 19. UK organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
  • Table 20. Germany organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 21. Germany organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
  • Table 22. France organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 23. France organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
  • Table 24. Italy organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 25. Italy organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
  • Table 26. Spain organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 27. Spain organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
  • Table 28. Denmark organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 29. Denmark organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
  • Table 30. Sweden organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 31. Sweden organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
  • Table 32. Norway organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 33. Norway organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
  • Table 34. Asia Pacific organ transplant immunosuppressant drugs market, by country, 2018 - 2030 (USD Million)
  • Table 35. Asia Pacific organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 36. Asia Pacific organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
  • Table 37. Japan organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 38. Japan organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
  • Table 39. China organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 40. China organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
  • Table 41. India organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 42. India organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
  • Table 43. Australia organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 44. Australia organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
  • Table 45. South Korea organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 46. South Korea organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
  • Table 47. Thailand organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 48. Thailand organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
  • Table 49. Latin America organ transplant immunosuppressant drugs market, by country, 2018 - 2030 (USD Million)
  • Table 50. Latin America organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 51. Latin America organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
  • Table 52. Brazil organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 53. Brazil organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
  • Table 54. Argentina organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 55. Argentina organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
  • Table 56. Middle East & Africa Organ transplant immunosuppressant drugs market, by country, 2018 - 2030 (USD Million)
  • Table 57. Middle East & Africa organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 58. Middle East & Africa organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
  • Table 59. South Africa organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 60. South Africa organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
  • Table 61. Saudi Arabia organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 62. Saudi Arabia organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
  • Table 63. UAE organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 64. UAE organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
  • Table 65. Kuwait organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 66. Kuwait organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Organ transplant immunosuppressant drugs market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Drug class and transplant type outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Organ transplant immunosuppressant drugs market dynamics
  • Fig. 12 Organ transplant immunosuppressant drugs market: Porter's five forces analysis
  • Fig. 13 Organ transplant immunosuppressant drugs market: PESTLE analysis
  • Fig. 14 Organ transplant immunosuppressant drugs market: Drug class segment dashboard
  • Fig. 15 Organ transplant immunosuppressant drugs market: Drug class market share analysis, 2024 & 2030
  • Fig. 16 Calcineurin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 17 Antiproliferative agents market, 2018 - 2030 (USD Million)
  • Fig. 18 mTOR inhibitor market, 2018 - 2030 (USD Million)
  • Fig. 19 Steroids market, 2018 - 2030 (USD Million)
  • Fig. 20 Other drug classes market, 2018 - 2030 (USD Million)
  • Fig. 21 Organ transplant immunosuppressant drugs market: Transplant type segment dashboard
  • Fig. 22 Organ transplant immunosuppressant drugs market: Transplant type market share analysis, 2024 & 2030
  • Fig. 23 Kidney market, 2018 - 2030 (USD Million)
  • Fig. 24 Liver market, 2018 - 2030 (USD Million)
  • Fig. 25 Heart market, 2018 - 2030 (USD Million)
  • Fig. 26 Lung market, 2018 - 2030 (USD Million)
  • Fig. 27 Pancreas market, 2018 - 2030 (USD Million)
  • Fig. 28 Other transplant types market, 2018 - 2030 (USD Million)
  • Fig. 29 Organ transplant immunosuppressant drugs market revenue, by region
  • Fig. 30 Regional marketplace: Key takeaways
  • Fig. 31 Regional marketplace: Key takeaways
  • Fig. 32 North America organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
  • Fig. 33 US country dynamics
  • Fig. 34 US organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
  • Fig. 35 Canada country dynamics
  • Fig. 36 Canada organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
  • Fig. 37 Mexico country dynamics
  • Fig. 38 Mexico organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
  • Fig. 39 Europe organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
  • Fig. 40 UK country dynamics
  • Fig. 41 UK organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
  • Fig. 42 Germany country dynamics
  • Fig. 43 Germany organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
  • Fig. 44 France country dynamics
  • Fig. 45 France organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
  • Fig. 46 Italy country dynamics
  • Fig. 47 Italy organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
  • Fig. 48 Spain country dynamics
  • Fig. 49 Spain organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
  • Fig. 50 Denmark country dynamics
  • Fig. 51 Denmark organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
  • Fig. 52 Sweden country dynamics
  • Fig. 53 Sweden organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
  • Fig. 54 Norway country dynamics
  • Fig. 55 Norway organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
  • Fig. 56 Asia Pacific organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
  • Fig. 57 Japan country dynamics
  • Fig. 58 Japan organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
  • Fig. 59 China country dynamics
  • Fig. 60 China organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
  • Fig. 61 India country dynamics
  • Fig. 62 India organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
  • Fig. 63 Australia country dynamics
  • Fig. 64 Australia organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
  • Fig. 65 South Korea country dynamics
  • Fig. 66 South Korea organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
  • Fig. 67 Thailand country dynamics
  • Fig. 68 Thailand organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
  • Fig. 69 Latin America organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
  • Fig. 70 Brazil country dynamics
  • Fig. 71 Brazil organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
  • Fig. 72 Argentina country dynamics
  • Fig. 73 Argentina organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
  • Fig. 74 MEA organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
  • Fig. 75 South Africa country dynamics
  • Fig. 76 South Africa organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
  • Fig. 77 Saudi Arabia country dynamics
  • Fig. 78 Saudi Arabia organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
  • Fig. 79 UAE country dynamics
  • Fig. 80 UAE organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
  • Fig. 81 Kuwait country dynamics
  • Fig. 82 Kuwait organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
  • Fig. 83 Company categorization
  • Fig. 84 Company market position analysis
  • Fig. 85 Strategic framework